Cortexyme (CRTX) Competitors $1.68 -0.01 (-0.59%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, IKT, PLX, IZTC, CVM, ZIVO, JATT, and CLDIShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), and Calidi Biotherapeutics (CLDI). Cortexyme vs. Its Competitors Omnicell HealthStream Veradigm Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience JATT Acquisition Calidi Biotherapeutics Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Do analysts prefer CRTX or OMCL? Omnicell has a consensus price target of $45.33, indicating a potential upside of 52.33%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 Do institutionals & insiders believe in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 2.5% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.57Omnicell$1.11B1.25$12.53M$0.5059.52 Which has more volatility & risk, CRTX or OMCL? Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Does the media prefer CRTX or OMCL? In the previous week, Omnicell had 19 more articles in the media than Cortexyme. MarketBeat recorded 20 mentions for Omnicell and 1 mentions for Cortexyme. Omnicell's average media sentiment score of 0.65 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cortexyme 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is CRTX or OMCL more profitable? Omnicell has a net margin of 2.01% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 2.01%4.27%2.44% SummaryOmnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.65M$274.13M$5.52B$9.37BDividend YieldN/AN/A4.74%4.13%P/E Ratio-0.57N/A28.9923.78Price / SalesN/A327.48440.5195.88Price / CashN/A22.4435.0756.59Price / Book0.4210.418.255.54Net Income-$89.94M-$106.40M$3.25B$259.97M7 Day Performance-9.19%-7.56%-3.75%-4.67%1 Month Performance5.00%16.68%2.99%3.29%1 Year Performance140.00%6.99%25.34%17.92% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.68-0.6%N/A+125.9%$50.65MN/A-0.5755News CoverageOMCLOmnicell3.602 of 5 stars$28.93-0.3%$45.33+56.7%-24.1%$1.35B$1.11B62.883,670Trending NewsEarnings ReportHSTMHealthStream4.3546 of 5 stars$26.81+0.1%$31.50+17.5%-12.3%$818.09M$291.65M42.551,093News CoverageUpcoming EarningsMDRXVeradigm2.6737 of 5 stars$4.65-0.6%$13.00+179.6%-49.7%$503.43M$1.53B0.008,000Gap DownIKTInhibikase Therapeutics1.6615 of 5 stars$1.78+0.3%$6.50+266.2%+14.3%$131.96MN/A-0.666News CoveragePLXProtalix BioTherapeutics2.4063 of 5 stars$1.53+1.7%$15.00+883.6%+38.1%$121.40M$59.76M-11.73200News CoverageIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpCVMCEL-SCI1.1136 of 5 stars$8.20-4.8%N/A-72.4%$43.69MN/A-17.1043News CoveragePositive NewsShort Interest ↑ZIVOZIVO BioscienceN/A$10.70-3.2%N/A+17.3%$40.84M$15.85K-2.1910JATTJATT AcquisitionN/A$1.64-2.4%N/A-60.1%$28.29MN/A0.003Gap DownHigh Trading VolumeCLDICalidi Biotherapeutics0.2995 of 5 stars$0.74+35.2%N/A-61.4%$26.99MN/A0.0038Short Interest ↑Gap DownHigh Trading Volume Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Invizyne Technologies Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives JATT Acquisition Alternatives Calidi Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
